INSPIRE (858070)

  https://cordis.europa.eu/project/id/858070

  Horizon 2020 (2014-2020)

  INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

  Innovative Training Networks (MSCA-ITN-2019)

  drug discovery  ·  software  ·  spectroscopy

  2020-01-01 Start Date (YY-MM-DD)

  2024-05-31 End Date (YY-MM-DD)

  € 4,021,968 Total Cost


  Description

New drug candidates often have off-target effects resulting in adverse events, thus representing a major limitation for drug R&D. Safety Pharmacology (SP) aims to detect, understand and reduce undesirable pharmacodynamic effects early-on. Especially, cardiovascular (CV) toxicity is problematic, as it is the most prevalent reason for failure during preclinical development. Moreover, CV toxicity remains a key reason for drug attrition during clinical development and beyond. This indicates current SP screens fail to detect a number of (late-onset) functional or structural CV toxicities. Additionally, SP uses a significant number of laboratory animals, thereby creating opportunities for a better implementation of the 3Rs. The vision of INSPIRE is to advance and “inspire” SP by exploring new technological capabilities (WP1), addressing emerging CV concerns (WP2) and delivering new validated solutions for CV safety screening (WP3). To this end, INSPIRE unites expertise from academic teams, technology-providers, pharmaceutical companies, regulators and hospitals to create a European training platform for 15 Early Stage Researchers (ESRs). Key innovative aspects of INSPIRE include: i) in vitro humanized cardiomyocytes assays, ii) unparalleled in vivo hardware/software solutions, iii) in silico predictions of haemodynamics, iv) mass spectroscopy imaging of drug exposure, v) exploration of mechanisms of late-onset CV toxicity, as observed in cardio-oncology, and vi) early integration of feedback from industry and regulators. Overall, INSPIRE constitutes a multidisciplinary and intersectoral training programme (WP4) with a balanced combination of hands-on research training, intersectoral secondments, local courses and network-wide events on scientific and transferable skills, enabling future R&I collaborations. Hence, INSPIRE will equip the future generation of SP scientists with a wide range of scientific knowledge and the ability to adapt to a dynamic ever-changing industry.


  Complicit Organisations

1 Israeli organisation participates in INSPIRE.

Country Organisation (ID) VAT Number Role Activity Type Total Cost EC Contribution Net EC Contribution
France INSTITUT NATIONAL DE RECHERCHE EN INFORMATIQUE ET AUTOMATIQUE (999547074) FR45180089047 participant REC € 274,802 € 274,802 € 274,802
Belgium UNIVERSITEIT ANTWERPEN (999902870) BE0257216482 coordinator HES € 768,960 € 768,960 € 768,960
Germany TSE SYSTEMS GMBH (998326814) DE114222856 participant PRC € 252,788 € 252,788 € 252,788
Belgium UCB BIOPHARMA (937666409) BE0543573053 participant PRC € 256,320 € 256,320 € 256,320
Israel WEIZMANN INSTITUTE OF SCIENCE (999979306) IL520016858 participant HES € 263,500 € 263,500 € 263,500
Netherlands UNIVERSITEIT MAASTRICHT (999975911) NL003475268B01 participant HES € 531,239 € 531,239 € 531,239
Germany BOEHRINGER INGELHEIM PHARMA GMBH &CO KG (994623839) DE143290578 participant PRC € 252,788 € 252,788 € 252,788
Netherlands NCARDIA BV (968020425) NL823044841B01 participant PRC € 0 € 0 € 0
France NOTOCORD SYSTEMS (952816063) FR28350927349 participant PRC € 549,604 € 549,604 € 549,604
Netherlands NCARDIA SERVICES BV (895458605) NL860951236B01 participant PRC € 265,619 € 265,619 € 265,619
United Kingdom THE UNIVERSITY OF NOTTINGHAM (999976978) GB690391225 participant HES € 606,345 € 606,345 € 606,345